慢性鼻窦炎伴鼻息肉和哮喘术后抗IgE治疗:疗效与预后因素
这项前瞻性观察研究纳入60例接受内镜鼻窦手术的慢性鼻窦炎伴鼻息肉和哮喘患者,分为标准治疗对照组和奥马珠单抗联合标准治疗组。治疗后6个月,奥马珠单抗组鼻窦炎控制应答率40%高于对照组14.3%(p=0.009),鼻部症状总分、嗅觉丧失评分和SNOT-22改善均更优,安全性良好。
要点
- 术后6个月奥马珠单抗组鼻窦炎控制应答率40% vs 对照组14.3%(p=0.009)。
- 奥马珠单抗组鼻部症状总分、嗅觉丧失评分和SNOT-22较基线改善优于对照组。
- 奥马珠单抗联合标准治疗安全性良好,可作为术后辅助治疗。
核心结论
- 奥马珠单抗在术后6个月显著改善慢性鼻窦炎伴鼻息肉和哮喘患者的临床结局,凸显其作为术后辅助治疗的潜力。
研究设计与样本
- 前瞻性观察研究,纳入2020年1月至2023年3月接受内镜鼻窦手术的60例慢性鼻窦炎伴鼻息肉和哮喘患者。
- 分为对照组(接受鼻盐水冲洗和布地奈德鼻喷剂标准治疗)和奥马珠单抗组(在标准治疗基础上加用奥马珠单抗)。
- 奥马珠单抗组30例和对照组28例完成治疗和随访。
主要发现
- 治疗6个月时,奥马珠单抗组鼻窦炎控制应答率为40%,对照组为14.3%(p=0.009)。
- 奥马珠单抗组鼻部症状总分、嗅觉丧失评分和SNOT-22评分较基线的平均改善均大于对照组。
- 治疗显示出良好的安全性。
关键数值与推荐
- 鼻窦炎疾病控制依据欧洲鼻窦炎和鼻息肉立场文件(EPOS)分为控制、部分控制或未控制。
临床怎么用
- 作者认为奥马珠单抗可作为慢性鼻窦炎伴鼻息肉和哮喘患者术后管理的有效辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Omalizumab has demonstrated efficacy in treating chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma (NPwAS) in preoperative settings. However, real-world evidence regarding its postoperative application remains limited. This study aimed to assess the effectiveness and safety of omalizumab in managing NPwAS following endoscopic sinus surgery (ESS), and to identify predictors for treatment response. METHODS: This prospective observational study enrolled 60 NPwAS patients who underwent ESS between January 2020 and March 2023. Participants were divided into two groups: Control group (receiving standard care: nasal saline lavage and budesonide nasal spray) and Omalizumab group (receiving omalizumab in addition to standard care). Disease assessments, including total nasal symptom score (TNSS), visual analog scale (VAS) score, asthma control test (ACT), and sino-nasal outcome test-22 (SNOT-22), were conducted at baseline and 6 months post-treatment. Blood and nasal polyp tissue samples were collected to explore potential predictors. CRS disease control was categorized as controlled, partly controlled, or uncontrolled based on the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS). RESULTS: Thirty patients in the Omalizumab group and 28 in the Control group completed the treatment and follow-up. At 6 months, CRS control was significantly better in the Omalizumab group compared to the Control group, with response rates of 40% and 14.3%, respectively (p = 0.009). The Omalizumab group also demonstrated greater mean improvements from baseline in TNSS, loss of smell score, and SNOT-22 score compared to the Control group. The treatment exhibited a favorable safety profile. CONCLUSIONS: Omalizumab significantly improved clinical outcomes in NPwAS patients 6 months post-surgery, underscoring its potential as an effective adjunctive therapy in the postoperative management of NPwAS.
引用
- Yang X, Ye M, Pan M, et al. Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors. Int Forum Allergy Rhinol. 2025. PMID: 40600899. doi:10.1002/alr.23626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。